The PennZone

  • Home
  • Non-profit
  • Books
  • Marketing
  • Health
  • Entertainment
  • Sports
  • Business
  • Legal

Olympus Acquires Veran Medical Technologies, Inc.
The PennZone/10102444

Trending...
  • One Night. One Encounter. A New Season Of Purpose
  • Dynamic Relaunch as AI Predictive Cybersecurity Company Optimized to Prevent Threats Proactively: Cycurion, Inc. (N A S D A Q: CYCU)
  • Expanding Into Medically Supervised Wellness With Major Apollo Wellness Centers Announcement; Sibannac, Inc. (Stock Symbol: SNNC)
CENTER VALLEY, Pa. and TOKYO, Dec. 30, 2020 /PRNewswire/ -- Olympus Corporation today announced that it has finalized the acquisition of Veran Medical Technologies, Inc. (VMT), a leading provider of advanced medical devices specializing in interventional pulmonology, following the definitive agreement the two companies signed December 4, 2020. With this acquisition by Olympus subsidiary Olympus Corporation of the Americas (OCA), Olympus gains VMT's global sales network, marketing, manufacturing, R&D, and other functions to expand the Olympus respiratory product portfolio.

Lung cancer is the leading cause of cancer-related deaths globally.1 With increased awareness and more lung cancer screenings using low-dose computed tomography (CT), the need for definitive diagnosis of lesions in the peripheral regions of the lungs by tissue biopsy is expected to increase. VMT's SPiN Thoracic Navigation System® and related devices are specifically designed to help physicians navigate to, localize, and sample peripheral pulmonary lesions. Together with the existing Olympus respiratory portfolio that includes radial endobronchial ultrasound (EBUS) and thin bronchoscopes, VMT's navigational system and related devices provide a powerful combination of imaging, access and precision for pulmonologists seeking to diagnose and determine the stage of a patient's lung cancer.

More on The PennZone
  • Communities In Schools of Eastern Pennsylvania Honors United Way and Local Leaders
  • New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
  • Veterans Day Breakfast Celebration in Valley Forge to Honor America's Military Heroes
  • Best Black Friday 2026 Deals on Lightweight Foldable Electric Wheelchairs – Save Up to 60%

"We are very excited about the synergies this acquisition creates. With the deal now closed, as one company we are able to combine Olympus' expertise and clinical history in minimally invasive technology with the innovation in navigation systems of Veran Medical Technology to improve workflow and patient care in lung cancer," said Lynn Ray, Vice President and General Manager of the Global Respiratory Business Unit for Olympus Corporation. "Olympus is committed to providing the medical community with the best tools possible to use in their fight against cancer. With the advent of EBUS-guided transbronchial needle aspiration (EBUS-TBNA) in 2004, Olympus brought patients the benefit of more accurate diagnosis and staging, to improve patient outcomes and care. We are thrilled to be at the forefront of development in this rapidly evolving area of respiratory care."

The acquisition will provide immediate incremental revenue and an experienced sales team within the U.S. market. VMT's advanced and proven navigation technology, together with Olympus' respiratory portfolio, strengthens and enhances Olympus' global position as a medical technology innovator.

As part of its current Corporate Strategy, Olympus vowed to "focus and scale" its Therapeutic solutions Division (TSD). To accelerate the process and provide greater agility, Olympus made OCA the TSD headquarters, recognizing the significant growth opportunities in North America. Olympus also identified three core medical fields to prioritize and has since focused on gastroenterological endotherapy devices, urological devices, and respiratory devices. The VMT acquisition is centered on respiratory devices and will position Olympus as a leader in this field.

More on The PennZone
  • Immerse Yourself in the Historic Tochigi Autumn Festival, Celebrated Every Two Years Since 1874
  • Resident Inspect Expands Virtual Property Inspections With AppFolio and Rentvine Integrations
  • Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA)
  • Dr. Marilyn Pendelton Releases The Grief Reset to Address Grief Beyond Death
  • AeroNet Deploys netElastic vBNG and CGNAT with Tarana Wireless to Deliver Scalable, Fiber-Class Broadband Across Puerto Rico

For additional information, please refer to our corporate disclosure, "Notice regarding acquisition of Veran Medical Technologies, Inc. in the United States."

(available at: https://www.olympus-global.com/news/ir/2020/)

1 WHO data:  https://www.who.int/news-room/fact-sheets/detail/cancer

About Olympus' Therapeutic Solutions Division
In its Therapeutic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Starting with its early contributions to the development of the polypectomy snare, Olympus' Therapeutic Solutions portfolio has grown to include an array of surgical energy devices and a wide range of instruments to help prevent, detect, and treat disease. For more information, visit www.olympus-global.com.

SOURCE Olympus

Related Links

http://www.olympus.com/
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Extreme Lead Program Highlights $27 Real Human Traffic Test for Affiliate and Network Marketers
  • Longevity Academy Features Gail Humble, MD of KLOTHO SKIN in the Longevity Leaders Project
  • Datavalet Named One of Quebec's Best Workplaces™ for 2026
  • Phinge Corporation Engages Sheridan Ross PC for Certain Intellectual Property Matters
  • Alan Hamilton of Shiver Hamilton Campbell Inducted as a Fellow of the American College of Trial Lawyers
  • Slotozilla Hosts Exclusive Halloween Casino Bonuses for 2026
  • One Night. One Encounter. A New Season Of Purpose
  • "BROOKLYN, BROOKLYN, BROOKLYN" children's book and official YouTube channel launch on October 27th
  • Expanding Into Medically Supervised Wellness With Major Apollo Wellness Centers Announcement; Sibannac, Inc. (Stock Symbol: SNNC)
  • Nextlink Internet Deploys netElastic to Modernize Its Hybrid Broadband Network
  • Dynamic Relaunch as AI Predictive Cybersecurity Company Optimized to Prevent Threats Proactively: Cycurion, Inc. (N A S D A Q: CYCU)
  • EMBER™ Unveils the Workplace Identity Score™ (WIS™), the First Standard for Measuring Workplace Impact on Workforce Performance & Business Growth
  • With Oil Prices Surging…Sky Quarry's Nevada Refinery Is Back in Action — CEO Highlights a Powerful New Growth Chapter for (N A S D A Q: SKYQ)
  • Preston Dermatology & Skin Surgery Center and Dr. Sheel Desai Solomon Win Gold in Raleigh's Best Awards for Second Consecutive Year
  • We are Talker Study: 64% of AI Users Have Bought From a Brand AI Introduced, as The Invisible Shortlist Reshapes Brand Discovery
  • One in three Americans may have lost track of retirement savings from a previous job
  • Political Concerns Drive US Investors to Golden Visas
  • The Truth Makers: The Quantum Lie Turns a Presidential Bribery Video Into a Crisis of Reality
  • 2027 Health Insurance Open Enrollment
  • Ryan J. Murphy Named as 2026 Irish Legal 100 Honoree

Popular on PennZone

  • SMACK Fighting Championships Announces Influencer Fight Night at Harrah's Philadelphia - 177
  • BJJ App mmaGPT Expands Academy Program to Support Jiu-Jitsu Instructors with AI Technique Coaching
  • New Children's Picture Book "Tippy Tay" Explores the Dangers of Peer Pressure and the Importance of
  • New Children's Picture Book "Adam's Apple" Celebrates Childhood Curiosity and the Funny Misundersta
  • RAS AP Consulting Issues National Compliance Alert and Launches Q4 2026 AP Readiness Program Ahead of IRS FIRE → IRIS Cutover
  • ASSIST Software Wins Volkswagen Challenge for Automated Quality Inspection
  • Wilson Venture Capital to Launch News Organization; Will Name Trevor Wilson CEO
  • LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports
  • Pittsburgh Digital Marketing Agency Moves to Babcock Boulevard in the North Hills
  • Turnstone Creative Welcomes Giovanni Amodei as Manager of Strategic Growth

Similar on PennZone

  • Steve Weclew is Appointed by STS Capital Partners as Managing Director
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
  • Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA)
  • New Atlas Maps the 38 States Behind Every Conversation
  • NECP Promotes Chertova to Senior Business Analyst
  • Security Industry Veteran Anthony Rumore Launches AegisLead to Help Security Companies Find Business and Manage Growth
  • Canadian Woman Plants 1,667 Love Stories in a Field of Peonies That Could Bloom for 100 Years
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
  • Access Control Security Shares 5 Ways Retailers Can Prevent Holiday Theft
  • Longevity Academy Features Gail Humble, MD of KLOTHO SKIN in the Longevity Leaders Project
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us